Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Alemtuzumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cellectis To Present Development Update For Eti-Cel at ASH 2025
    Cellectis To Present Development Update For Eti-Cel at ASH 2025

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179424/0/en/Cellectis-to-Present-a-Development-Update-for-eti-cel-at-ASH-2025.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Cellectis Provides Financial Results for the Second Quarter 2024
    Cellectis Provides Financial Results for the Second Quarter 2024

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925531/0/en/Cellectis-Provides-Financial-Results-for-the-Second-Quarter-2024.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    FDA Grants Orphan Drug Designation To Cellectis' CLLS52 For ALL
    FDA Grants Orphan Drug Designation To Cellectis' CLLS52 For ALL

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2923264/0/en/FDA-Grants-Orphan-Drug-Designation-to-Cellectis-CLLS52-alemtuzumab-For-ALL-Treatment.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share
    Genzyme`s Lemtrada (alemtuzumab) Receives Suppl Approval in the U.S.
    Genzyme`s Lemtrada (alemtuzumab) Receives Suppl Approval in the U.S.

    20 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    20 May 2024
    Share Share
    Genzyme`s Campath (alemtuzumab) Receives Suppl Approval in the U.S.
    Genzyme`s Campath (alemtuzumab) Receives Suppl Approval in the U.S.

    20 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    20 May 2024
    Share Share
    Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.
    Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.

    08 Feb 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    08 Feb 2024
    Share Share